What are PLK1 inhibitor drugs?

PLK1 inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting PLK1 (Polo-like kinase 1)). 0 are currently marketed, with 3 more in clinical development.

PLK1 inhibitor

0 marketed 3 in Phase 3

This page covers all PLK1 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PLK1 (Polo-like kinase 1), Plk1.

Targets

PLK1 (Polo-like kinase 1) · Plk1

Phase 3 pipeline (3)

PLX-200 · Polaryx Therapeutics, Inc. · Oncology
PLX-200 is a selective inhibitor of polo-like kinase 1 (PLK1) that disrupts cell cycle progression and induces apoptosis in cancer cells.
SPI-2012 · Spectrum Pharmaceuticals, Inc · Oncology
SPI-2012 is a selective inhibitor of polo-like kinase 1 (PLK1) that disrupts cell cycle progression and induces apoptosis in cancer cells.
Utidelone plus Intermittent Capecitabine · Sun Yat-sen University · Oncology
Utidelone is a novel, orally administered, small molecule inhibitor of the polo-like kinase 1 (Plk1), which plays a critical role in cell cycle progression and is overexpressed in various cancers.